Medtronic ROA 2006-2018 | MDT
Current and historical return on assets (ROA) values for Medtronic (MDT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Medtronic ROA for the three months ending July 31, 2018 was 7.10%.
| Medtronic ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-07-31 | $3.16B | $89.72B | 3.41% |
| 2018-04-30 | $3.10B | $91.39B | 3.25% |
| 2018-01-31 | $2.81B | $95.80B | 2.88% |
| 2017-10-31 | $5.02B | $94.46B | 5.12% |
| 2017-07-31 | $4.12B | $100.25B | 4.16% |
| 2017-04-30 | $4.03B | $99.86B | 4.08% |
| 2017-01-31 | $3.97B | $97.58B | 4.03% |
| 2016-10-31 | $4.24B | $98.41B | 4.25% |
| 2016-07-31 | $3.65B | $98.60B | 3.59% |
| 2016-04-30 | $3.54B | $99.64B | 3.44% |
| 2016-01-31 | $2.43B | $102.71B | 2.32% |
| 2015-10-31 | $2.32B | $104.95B | 2.49% |
| 2015-07-31 | $2.62B | $104.63B | 3.44% |
| 2015-04-30 | $2.68B | $106.69B | 4.49% |
| 2015-01-31 | $3.12B | $55.23B | 7.37% |
| 2014-10-31 | $2.91B | $38.78B | 7.68% |
| 2014-07-31 | $2.98B | $37.55B | 8.00% |
| 2014-04-30 | $3.07B | $37.94B | 8.36% |
| 2014-01-31 | $3.59B | $37.23B | 9.99% |
| 2013-10-31 | $3.81B | $36.47B | 10.79% |
| 2013-07-31 | $3.56B | $34.97B | 10.25% |
| 2013-04-30 | $3.47B | $34.90B | 10.12% |
| 2013-01-31 | $3.49B | $34.95B | 10.34% |
| 2012-10-31 | $3.44B | $33.96B | 10.41% |
| 2012-07-31 | $3.66B | $33.25B | 11.28% |
| 2012-04-30 | $3.62B | $32.82B | 11.34% |
| 2012-01-31 | $3.40B | $31.91B | 10.85% |
| 2011-10-31 | $3.39B | $31.75B | 10.93% |
| 2011-07-31 | $3.09B | $31.09B | 10.15% |
| 2011-04-30 | $3.10B | $30.68B | 10.39% |
| 2011-01-31 | $3.28B | $30.60B | 11.23% |
| 2010-10-31 | $3.18B | $29.31B | 11.44% |
| 2010-07-31 | $3.48B | $28.66B | 13.12% |
| 2010-04-30 | $3.10B | $28.09B | 12.26% |
| 2010-01-31 | $2.25B | $25.17B | 9.30% |
| 2009-10-31 | $2.11B | $24.28B | 8.97% |
| 2009-07-31 | $1.79B | $23.57B | 7.79% |
| 2009-04-30 | $2.07B | $23.59B | 9.09% |
| 2009-01-31 | $2.69B | $22.76B | 11.98% |
| 2008-10-31 | $2.07B | $22.03B | 9.36% |
| 2008-07-31 | $2.19B | $22.73B | 10.06% |
| 2008-04-30 | $2.14B | $22.20B | 10.20% |
| 2008-01-31 | $2.23B | $21.41B | 10.99% |
| 2007-10-31 | $2.86B | $20.59B | 14.44% |
| 2007-07-31 | $2.88B | $19.66B | 14.83% |
| 2007-04-30 | $2.80B | $19.51B | 14.34% |
| 2007-01-31 | $2.73B | $19.57B | 13.94% |
| 2006-10-31 | $2.69B | $18.90B | 13.95% |
| 2006-07-31 | $2.83B | $20.18B | 14.88% |
| 2006-04-30 | $2.55B | $19.67B | 14.02% |
| 2006-01-31 | $2.00B | $18.34B | 11.50% |
| 2005-10-31 | $1.88B | $17.77B | 11.21% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $124.396B | $29.953B |
| Medtronic Public Limited Company, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $121.907B | 24.70 |
| Stryker (SYK) | United States | $62.115B | 23.41 |
| Boston Scientific (BSX) | United States | $50.107B | 25.32 |
| Baxter (BAX) | United States | $33.967B | 21.93 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.913B | 14.86 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.016B | 0.00 |
| ResMed (RMD) | United States | $14.484B | 27.62 |
| Perrigo (PRGO) | Ireland | $8.621B | 13.09 |
| Bio-Rad Laboratories (BIO) | United States | $8.038B | 51.40 |
| Canopy Growth (CGC) | Canada | $7.963B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.061B | 19.22 |
| Aurora Cannabis (ACB) | Canada | $5.941B | 32.42 |
| Haemonetics (HAE) | United States | $5.495B | 48.32 |
| Hutchison China MediTech (HCM) | China | $5.011B | 0.00 |
| Insulet (PODD) | United States | $4.690B | 0.00 |
| ICU Medical (ICUI) | United States | $4.600B | 25.63 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.898B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.709B | 0.00 |
| National Vision Holdings (EYE) | United States | $3.224B | 62.36 |
| Neogen (NEOG) | United States | $3.190B | 48.31 |
| NuVasive (NUVA) | United States | $3.045B | 28.33 |
| Quidel (QDEL) | United States | $2.390B | 31.16 |
| Aphria (APHA) | $2.383B | 0.00 | |
| NxStage Medical (NXTM) | United States | $1.935B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.455B | 20.60 |
| AtriCure (ATRC) | United States | $1.189B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.007B | 1450.50 |
| VAREX IMAGING (VREX) | United States | $0.933B | 18.74 |
| Meridian Bioscience (VIVO) | United States | $0.816B | 26.01 |
| Surmodics (SRDX) | United States | $0.775B | 118.39 |
| OraSure Technologies (OSUR) | United States | $0.771B | 43.38 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.738B | 23.67 |
| PetIQ (PETQ) | United States | $0.737B | 20.93 |
| MacroGenics (MGNX) | United States | $0.702B | 0.00 |
| Cerus (CERS) | United States | $0.685B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.604B | 18.68 |
| Omeros (OMER) | United States | $0.569B | 0.00 |
| Owens & Minor (OMI) | United States | $0.550B | 6.22 |
| Insys Therapeutics (INSY) | United States | $0.531B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.510B | 25.05 |
| NanoString Technologies (NSTG) | United States | $0.478B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.429B | 0.00 |
| Evolus (EOLS) | United States | $0.373B | 0.00 |
| Quanterix (QTRX) | United States | $0.361B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.326B | 21.11 |
| Cytosorbents (CTSO) | United States | $0.287B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.254B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.230B | 0.00 |
| Surface Oncology (SURF) | United States | $0.218B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.197B | 265.75 |
| Bovie Medical (BVX) | United States | $0.189B | 0.00 |
| Chimerix (CMRX) | United States | $0.168B | 0.00 |
| Fonar (FONR) | United States | $0.141B | 7.07 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.138B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.107B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.099B | 0.00 |
| United-Guardian (UG) | United States | $0.080B | 16.85 |
| Female Health (VERU) | United States | $0.077B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.071B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.068B | 21.53 |
| InfuSystems Holdings (INFU) | United States | $0.067B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.053B | 0.00 |
| Neurotrope (NTRP) | United States | $0.047B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.027B | 0.00 |
| Myomo (MYO) | United States | $0.024B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.018B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.017B | 0.00 |
| Senestech (SNES) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.000B | 0.00 |
